|
US4820715A
(en)
*
|
1984-06-28 |
1989-04-11 |
Bristol-Myers Company |
Anti-emetic quinuclidinyl benzamides
|
|
US5231170A
(en)
*
|
1986-08-27 |
1993-07-27 |
Paul Averback |
Antibodies to dense microspheres
|
|
US4816416A
(en)
*
|
1986-08-27 |
1989-03-28 |
Paul Averback |
Microspheric bodies for use in screening therapies for Azheimer's disease and related conditions
|
|
EP0272052B1
(de)
*
|
1986-12-16 |
1992-07-08 |
A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) |
Angstlösende N-(1-Azabicyclo[2.2.2)oct-3-yl)benzamide und -thiobenzamide
|
|
DE3752062T2
(de)
*
|
1986-12-17 |
1997-09-11 |
Glaxo Group Ltd |
Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
|
|
US5244909A
(en)
*
|
1986-12-17 |
1993-09-14 |
Glaxo Group Limited |
Methods for the treatment of cognitive disorders
|
|
US5190954A
(en)
*
|
1986-12-17 |
1993-03-02 |
Glaxo Group Limited |
Methods for the treatment of cognitive disorders
|
|
JP2608078B2
(ja)
*
|
1986-12-17 |
1997-05-07 |
グラクソ、グループ、リミテッド |
医 薬
|
|
US5246941A
(en)
*
|
1986-12-17 |
1993-09-21 |
Glaxo Group Limited |
Method for the treatment of depression
|
|
US5200414A
(en)
*
|
1986-12-17 |
1993-04-06 |
Glaxo Group Limited |
Methods for the treatment of cognitive disorders
|
|
GB8720805D0
(en)
*
|
1987-09-04 |
1987-10-14 |
Naylor R J |
2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
|
|
EP0311724A1
(de)
*
|
1987-10-16 |
1989-04-19 |
Synthelabo |
Anxiolytische R-N-(1-Azabicyclo[2.2.2]oct-3-yl)-benzamide und -thiobenzamide
|
|
US4863919A
(en)
*
|
1988-02-01 |
1989-09-05 |
A. H. Robins Company, Incorporated |
Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
|
|
EP0353371A1
(de)
*
|
1988-08-04 |
1990-02-07 |
Synthelabo |
Steigerung der Gedächtnisleistung durch R-N-(1-azabicyclo[2.2.2]oct-3-yl)Benzamide und Thiobenzamide
|
|
US5229407A
(en)
*
|
1988-09-01 |
1993-07-20 |
Glaxo Group Limited |
Medicaments
|
|
GB8820651D0
(en)
*
|
1988-09-01 |
1988-10-05 |
Glaxo Group Ltd |
Medicaments
|
|
DE4009565A1
(de)
*
|
1990-03-24 |
1991-09-26 |
Merck Patent Gmbh |
Indolderivate
|
|
EP0492020A1
(de)
*
|
1990-12-21 |
1992-07-01 |
Merrell Dow Pharmaceuticals Inc. |
Verwendung von bestimmten Estern von Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-on und verwandter Verbindungen zur Behandlung von kognitiven Erkrankungen
|
|
ZA92278B
(en)
*
|
1991-02-01 |
1992-10-28 |
Akzo Nv |
3-quinuclidine derivatives
|
|
AU654013B2
(en)
*
|
1991-03-13 |
1994-10-20 |
Regents Of The University Of Minnesota |
2-hydroxy-3(4-iodophenyl)-1-(4-phenylpiperidinyl) propane
|
|
IT1250629B
(it)
*
|
1991-07-04 |
1995-04-21 |
Boehringer Ingelheim Italia |
Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
|
|
US5723103A
(en)
*
|
1994-12-09 |
1998-03-03 |
Vanderbilt University |
Substituted benzamides and radioligand analogs and methods of use
|
|
SE0000540D0
(sv)
*
|
2000-02-18 |
2000-02-18 |
Astrazeneca Ab |
New compounds
|
|
WO2002016357A2
(en)
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
JP2004506735A
(ja)
|
2000-08-18 |
2004-03-04 |
ファルマシア・アンド・アップジョン・カンパニー |
疾患治療用キヌクリジン置換アリール化合物
|
|
WO2002017358A2
(en)
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
|
|
WO2002015662A2
(en)
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
|
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
|
JP2005504058A
(ja)
|
2001-08-24 |
2005-02-10 |
ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー |
疾患の治療のための置換ヘテロアリール−7−アザ[2.2.1]ビシクロヘプタン
|
|
US20030069296A1
(en)
*
|
2001-08-24 |
2003-04-10 |
Wishka Donn G. |
Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
|
|
BR0212477A
(pt)
*
|
2001-09-12 |
2004-08-24 |
Upjohn Co |
7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
|
|
EA007429B1
(ru)
|
2001-10-02 |
2006-10-27 |
Фармация Энд Апджон Компани |
Азабициклические замещённые конденсированные гетероарильные соединения
|
|
WO2003032897A2
(en)
*
|
2001-10-16 |
2003-04-24 |
Astrazeneca Ab |
Azabicyclic compounds for the treatment of fibromyalgia syndrome
|
|
MXPA04003986A
(es)
*
|
2001-10-26 |
2004-07-23 |
Upjohn Co |
Carboxamidas hetero-biciclicas n-azabiciclico sustituidas como agonistas nachr.
|
|
US6849620B2
(en)
|
2001-10-26 |
2005-02-01 |
Pfizer Inc |
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
|
|
US6919359B2
(en)
*
|
2001-11-08 |
2005-07-19 |
Pfizer Inc |
Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
|
|
WO2003042210A1
(en)
|
2001-11-09 |
2003-05-22 |
Pharmacia & Upjohn Company |
Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
|
|
DE10162375A1
(de)
|
2001-12-19 |
2003-07-10 |
Bayer Ag |
Bicyclische N-Aryl-amide
|
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
|
US6852716B2
(en)
|
2002-02-15 |
2005-02-08 |
Pfizer Inc |
Substituted-aryl compounds for treatment of disease
|
|
EP1476448A2
(de)
*
|
2002-02-19 |
2004-11-17 |
PHARMACIA & UPJOHN COMPANY |
Azabicyclische verbindungen zur behandlung von erkrankungen
|
|
BR0307735A
(pt)
*
|
2002-02-19 |
2005-01-25 |
Upjohn Co |
Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença
|
|
US7001900B2
(en)
*
|
2002-02-20 |
2006-02-21 |
Pfizer Inc. |
Azabicyclic compounds for the treatment of disease
|
|
DE10234424A1
(de)
|
2002-07-29 |
2004-02-12 |
Bayer Ag |
Benzothiophen-, Benzofuran- und Indolharnstoffe
|
|
AU2003253686A1
(en)
|
2002-08-01 |
2004-02-23 |
Pharmacia & Upjohn Company Llc |
1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
|
|
GB0220581D0
(en)
|
2002-09-04 |
2002-10-09 |
Novartis Ag |
Organic Compound
|
|
ES2405594T3
(es)
*
|
2002-09-25 |
2013-05-31 |
Memory Pharmaceuticals Corporation |
Idazoles, benzotiazoles y benzisotiazoles, y preparación y usos de los mismos
|
|
CA2503786A1
(en)
*
|
2002-11-01 |
2004-05-13 |
Pharmacia & Upjohn Company Llc |
Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases
|
|
WO2005063767A2
(en)
|
2003-12-22 |
2005-07-14 |
Memory Pharmaceuticals Corporation |
Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
|
|
RU2417225C2
(ru)
*
|
2004-03-25 |
2011-04-27 |
Мемори Фармасьютиклз Корпорейшн |
Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
|
|
CA2567977A1
(en)
*
|
2004-04-22 |
2006-01-05 |
Memory Pharmaceutical Corporation |
Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
|
|
JP2007538011A
(ja)
*
|
2004-05-07 |
2007-12-27 |
メモリー・ファーマシューティカルズ・コーポレイション |
1h−インダゾール、ベンゾチアゾール、1,2−ベンゾイソキサゾール、1,2−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
|
|
AR049401A1
(es)
|
2004-06-18 |
2006-07-26 |
Novartis Ag |
Aza-biciclononanos
|
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
|
JP2008525464A
(ja)
|
2004-12-22 |
2008-07-17 |
メモリー・ファーマシューティカルズ・コーポレイション |
α−7ニコチン性受容体リガンド並びにその製造及び使用
|
|
US8106066B2
(en)
|
2005-09-23 |
2012-01-31 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
|
|
GB0521508D0
(en)
|
2005-10-21 |
2005-11-30 |
Novartis Ag |
Organic compounds
|
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
|
US20080242688A1
(en)
*
|
2007-03-19 |
2008-10-02 |
Astrazeneca Ab |
Method 741
|
|
EP2344636B1
(de)
*
|
2008-10-09 |
2017-12-06 |
Howard Hughes Medical Institute |
Neue chimäre ligandgesteuerte ionenkanäle und anwendungsverfahren dafür
|
|
SI2540297T1
(sl)
|
2008-11-19 |
2015-08-31 |
Forum Pharmaceuticals Inc. |
Zdravljenje kognitivne motnje z (R)-7-Kloro-N-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid in farmacevtsko nje sprejemljivih soli
|
|
CN102802620A
(zh)
*
|
2009-05-11 |
2012-11-28 |
英维沃医药有限公司 |
使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
|
|
NZ603625A
(en)
|
2010-05-17 |
2014-10-31 |
Envivo Pharmaceuticals Inc |
A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
|
|
WO2013010679A1
(en)
|
2011-07-15 |
2013-01-24 |
Novartis Ag |
Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
|
|
EP3666272A1
(de)
|
2012-05-08 |
2020-06-17 |
Forum Pharmaceuticals Inc. |
Verwendung von encenicline bei der behandlung von kognitiver behinderung, alzheimer-krankheit, speicherdefizit
|
|
WO2017060287A1
(en)
*
|
2015-10-05 |
2017-04-13 |
Sandoz Ag |
Process for the preparation of encenicline from 7-chloro-benzo[b]thiophene-2-carboxylic acid chloride and (r)-quinuclidin-3-amine in the presence of imidazole
|